Abstract
The objective of this article was to identify adverse events that are generated as a result of the use of insulins Aspart, Glargine and Glulisine in patients with type 2 diabetes mellitus. For this purpose, an exhaustive bibliographic review was carried out in the Scopus and PubMed databases. Inclusion criteria were applied that limited the selection to open access controlled clinical trials that addressed the safety of the aforementioned insulins, excluding those articles that did not contain relevant information. 22 scientific articles were selected that were located in a total of 13 journals. 11 documents dealt with the topic of Insulin Glargine, 7 on Aspart and 4 on Glulisine. The year where most articles were found was 2019 (5). In total, 14 types of adverse events were identified, with hypoglycemia being the most representative with 39 cases and the event with the highest incidence of up to 62%. It is concluded that insulins, glargine, glulisine and aspart present a variety of adverse reactions, with hypoglycemic events being the most prevalent, especially with insulin aspart (0.006% - 62%). Other common effects include nausea, diarrhea and vomiting, with a higher incidence in treatments with glargine and aspartate.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call